Literature DB >> 12473651

Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer.

Jian Zhou1, Jessica Scholes, Jer-Tsong Hsieh.   

Abstract

DOC-2/DAB2 is a potent tumor suppressor in many cancer types including prostate cancer. In prostate cancer, expression of DOC-2/DAB2 can inhibit its growth. Our recent studies demonstrate that DOC-2/DAB2 can suppress both protein kinase C and peptide growth factor-elicited signal pathways via the Ras-mitogen-activated protein kinase pathway. In this study, we further showed that the proline-rich domain of DOC-2/DAB2 could also interact with proteins containing the Src homology 3 domain, such as Src and Fgr. The binding of c-Src to DOC-2/DAB2 was enhanced in cells treated with growth factor, and this interaction resulted in c-Src inactivation. The c-Src inactivation was evidenced by the decreased tyrosine 416 phosphorylation of c-Src and reduced downstream effector activation. It appears that DOC-2/DAB2 can bind to Src homology 3 domain of c-Src and maintain it in an inactive conformation. Thus, this study provides a new mechanism for modulating c-Src in prostatic epithelium and cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12473651     DOI: 10.1074/jbc.M210628200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

Review 1.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

2.  Negative regulation of the endocytic adaptor disabled-2 (Dab2) in mitosis.

Authors:  David Chetrit; Lior Barzilay; Galit Horn; Tom Bielik; Nechama I Smorodinsky; Marcelo Ehrlich
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

3.  Smooth muscle contraction and growth of stromal cells in the human prostate are both inhibited by the Src family kinase inhibitors, AZM475271 and PP2.

Authors:  Yiming Wang; Christian Gratzke; Alexander Tamalunas; Beata Rutz; Anna Ciotkowska; Frank Strittmatter; Annika Herlemann; Sophie Janich; Raphaela Waidelich; Chunxiao Liu; Christian G Stief; Martin Hennenberg
Journal:  Br J Pharmacol       Date:  2016-11-01       Impact factor: 8.739

Review 4.  Endocytic proteins in the regulation of nuclear signaling, transcription and tumorigenesis.

Authors:  Beata Pyrzynska; Iwona Pilecka; Marta Miaczynska
Journal:  Mol Oncol       Date:  2009-06-11       Impact factor: 6.603

5.  Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter.

Authors:  Adèle Hannigan; Paul Smith; Gabriela Kalna; Cristiana Lo Nigro; Clare Orange; Darren I O'Brien; Reshma Shah; Nelofer Syed; Lindsay C Spender; Blanca Herrera; Johanna K Thurlow; Laura Lattanzio; Martino Monteverde; Meghan E Maurer; Francesca M Buffa; Jelena Mann; David C K Chu; Catharine M L West; Max Patridge; Karin A Oien; Jonathan A Cooper; Margaret C Frame; Adrian L Harris; Louise Hiller; Linda J Nicholson; Milena Gasco; Tim Crook; Gareth J Inman
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

6.  Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy.

Authors:  Md Selim Ahmed; Se Eun Byeon; Yideul Jeong; Mohammad Alam Miah; Md Salahuddin; Yoon Lee; Sung-Soo Park; Yong-Soo Bae
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

7.  Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Diego F Calvisi; Sara Ladu; Alexis Gorden; Miriam Farina; Ju-Seog Lee; Elizabeth A Conner; Insa Schroeder; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

8.  Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma.

Authors:  Joanna H Tong; David C Ng; Shuk L Chau; Ken K So; Patrick P Leung; Tin L Lee; Raymond W Lung; Michael W Chan; Anthony W Chan; Kwok W Lo; Ka F To
Journal:  BMC Cancer       Date:  2010-06-03       Impact factor: 4.430

9.  HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms.

Authors:  C-H Chen; W-H Chang; K-Y Su; W-H Ku; G-C Chang; Q-S Hong; Y-J Hsiao; H-C Chen; H-Y Chen; R Wu; P-C Yang; J J W Chen; S-L Yu
Journal:  Oncogene       Date:  2016-04-11       Impact factor: 9.867

10.  Quantitative proteomics identifies a Dab2/integrin module regulating cell migration.

Authors:  Anjali Teckchandani; Natalie Toida; Jake Goodchild; Christine Henderson; Julian Watts; Bernd Wollscheid; Jonathan A Cooper
Journal:  J Cell Biol       Date:  2009-07-06       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.